{"id":44404,"date":"2022-06-30T11:14:42","date_gmt":"2022-06-30T11:14:42","guid":{"rendered":"https:\/\/biomedpharmajournal.org\/?p=44404"},"modified":"2022-07-19T08:12:28","modified_gmt":"2022-07-19T08:12:28","slug":"evaluation-of-serum-levels-of-tissue-inhibitor-metalloproteinase-1and-matrix-metalloproteinase-1-in-egyptian-patients-with-diabetic-nephropathy","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol15no2\/evaluation-of-serum-levels-of-tissue-inhibitor-metalloproteinase-1and-matrix-metalloproteinase-1-in-egyptian-patients-with-diabetic-nephropathy\/","title":{"rendered":"Evaluation of Serum Levels of Tissue Inhibitor Metalloproteinase-1and Matrix Metalloproteinase-1 in Egyptian Patients with Diabetic Nephropathy"},"content":{"rendered":"

Introduction<\/strong>\u00a0<\/strong><\/p>\n

Matrix metalloproteinases (MMPs) are a family of zinc and calcium dependent proteolytic enzymes that mediate the degradation of extracellular matrix 1<\/sup>2<\/sup>. The balance between metalloproteinase-1 (MMP-1) and tissue inhibitor metalloproteinase-1 (TIMP-1) is an imperative controller point in tissue remodeling and an imbalance could encourage destruction of tissue.\u00a0Evidence regarding altered MMP and TIMP activity in diabetes mellitus remains ambiguous. Moreover, although MMPs and TIMPs were investigated in the search for a possible role in diabetic nephropathy, they were not studied previously in the particular Egyptian clinical setting of type 2 diabetes mellitus. In the predominance of diabetic patients, albuminuria is one of the most common and earliest indicators of kidney illness3<\/sup>. Albuminuria regression is more common with ameliorations in triglycerides,HbA1c and blood pressure, as well as by using inhibitors of renin angiotensin aldosterone (RAAS). Another demographic predictors of regression versus progression have been discussed, comprising sex alterations, which has been debatable4<\/sup>.Data are limited regarding rates of albuminuria progression and regression. Since not all diabetic persons develop all the conceivable complications of the situation, systematic screening for pertinent complains has become a chief portion of diabetes care nowadays. Early detection of complexity permits definite treatment to delay progression of a complication or extra focused preventive treatment in its early phases.<\/p>\n

This work was designed for assessment of serum levels of MMP and TIMP in cases with type 2 diabetes with and without diabetic nephropathy and to assess the effects of diabetes on MMP-1 and TIMP-1 levels and to analyze these biomarkers to unmask early diabetic complications. Our hypothesis that high plasma levels of MMP-9 could be associated to chronic microvascular complications in persons with type 2 diabetes, as diabetes nephropathy.\u00a0<\/strong><\/p>\n

Subjects and Methods<\/strong> \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/strong><\/p>\n

A total of 60 patents with DM2 were recruited from outpatient clinics of National institute of diabetes and endocrinology; between December 2017 and November 2019. Their median age was 43.5 years (range, 34-50 years). There were 50 healthy volunteer controls without family history of DM2. The individual variability of these assays in a given patient did not exceed 10%.<\/p>\n

Blood samples were collected from all fasting participants in this study, Lipemic and hemolyzed samples were excluded.<\/p>\n

Assessment of Lipid profile<\/strong><\/p>\n

Total cholesterol (TC) and triglycerides (TG) in serum were measured by colourimetric enzymatic method5<\/sup> . Also, high-density lipoprotein cholesterol (HDL cholesterol) was measured6<\/sup> , and low-density lipoprotein cholesterol (LDL cholesterol) was evaluated by Friedewald formula 7<\/sup><\/p>\n

Quantification of MMP-1<\/strong><\/p>\n

Serum concentrations of MMP-1determined with enzyme linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN,USA).<\/p>\n

Quantification of TIMP-1<\/strong><\/p>\n

Serum concentrations of TIMP-1 determined with enzyme linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN,USA).<\/p>\n

Assessment of HbA1c<\/strong><\/p>\n

HbA1c levels were evaluated by high-performance liquid chromatography (BioRad).HbA1c by cation – exchange resin method8<\/sup> .<\/p>\n

Statistical analyses<\/strong><\/p>\n

Statistical analysis was performed using the statistical package for the social sciences, version 13 (SPSS Inc., Chicago, Illinois, USA). Data are presented as mean \u00b1 SD fornormal distribution samples, whereas the mean differences between two groups were compared by Student\u2019s t <\/em>test, and one-way analysis of variance was applied to three groups. Pearson\u2019s correlation (correlation coefficient) test was used for testingcorrelations between variables.A P <\/em>value less than 0.05 was considered statistically significant multiple linear regression analysis was performed to find significant determinants of both markers, including BMI, TG, HDL-C, SBP, and DBP with as independent variables. The descriptive statistics were presented as mean \u00b1 SD. Differences between groups were assessed by ANOVA for normally distributed measurement data, Wilcoxon\u2019s test for non-normally distributed measurement data. The distribution of the variables was examined using Kolmogorov\u2013Smirnov test of normality to verify whether it is followed a Gaussian pattern.<\/p>\n

Results<\/strong><\/p>\n

Table 1 shows that serum concentration of MMP-1 in diabetic nephropathy was considerably elevated when compared with healthy group and TIMP-1 was significantly increased when compared with control and DM2 groups.<\/em><\/p>\n

Table 2 displays patients and controls clinical characteristics. DN patients showed significant higher levels of BMI, HBLA1c, TG, LDL and low HDL than controls as well as compared to DM2 patients.<\/p>\n

Table 3\u2002shows significant positive correlations between serum levels of MMP-1, TIMP-1, FBG and HbA1c in DN group.<\/p>\n

In table 4, the outcome of stepwise multiple linear regression analysis including all the studied parameters including age, BMI, HpA1c, TC, TG, HDL and LDL as independent variables to find significant determinants for TIMP-1 and MMP-1 among DN patients.\u00a0 HbA1c, LDL, HDL and TG were selected for both TIMP-1 and MMP-1.<\/p>\n

Table 1: Serum MMP-1andTIMP- 1levels in controls and patients.<\/strong><\/p>\n\n\n\n\n\n\n
 <\/p>\n

Variables<\/td>\n

Control<\/td>\nT2Dwithout DN<\/td>\nDN<\/td>\n<\/tr>\n
Median (range)<\/td>\nMedian (range)<\/td>\nMedian (range)<\/td>\n<\/tr>\n
MMP-1<\/td>\n131.78 (102-361)<\/td>\n141.52(201-307)<\/td>\n153.60 (311-767) \u2020<\/td>\n<\/tr>\n
TIMP-1(ng\/mL)<\/td>\n540.84(398-497)<\/td>\n671.76 (599-960)<\/td>\n1209.26 (798-1699)\u2020<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

p<0.05, vs. ControlandT2D without DN<\/p>\n

Table 2: Patient characteristics and other clinical findings.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Variables<\/td>\nGroup<\/td>\nMean<\/td>\nSD<\/td>\nP value<\/td>\n<\/tr>\n
Age (years)<\/td>\nControl<\/td>\n45.80<\/td>\n1.98<\/td>\n0.67<\/td>\n<\/tr>\n
T2D without DN<\/td>\n46.40<\/td>\n2.01<\/td>\n<\/tr>\n
DN<\/td>\n48.90<\/td>\n1.52<\/td>\n<\/tr>\n
BMI (kg\/m2)<\/td>\nControl<\/td>\n20.04<\/td>\n3.4715<\/td>\n<0.001<\/td>\n<\/tr>\n
T2D without DN<\/td>\n23.66<\/td>\n3.83<\/td>\n<\/tr>\n
DN<\/td>\n28.04<\/td>\n2.17<\/td>\n<\/tr>\n
HbA1c<\/td>\nControl<\/td>\n3.99<\/td>\n0.50<\/td>\n <\/p>\n

<0.001<\/td>\n<\/tr>\n

T2Dwithout DN<\/td>\n4.45<\/td>\n0.75<\/td>\n<\/tr>\n
DN<\/td>\n7.60<\/td>\n.65<\/td>\n<\/tr>\n
 <\/p>\n

TC (mg\/dL)<\/td>\n

Control<\/td>\n136.29<\/td>\n26.17<\/td>\n0.69<\/td>\n<\/tr>\n
T2Dwithout DN<\/td>\n144.84<\/td>\n27.89<\/td>\n<\/tr>\n
DN<\/td>\n134.45<\/td>\n27.85<\/td>\n<\/tr>\n
TG(mg\/dL)<\/td>\nControl<\/td>\n77.87<\/td>\n28.28<\/td>\n<0.03<\/td>\n<\/tr>\n
T2Dwithout DN<\/td>\n92.42<\/td>\n22.12<\/td>\n<\/tr>\n
DN<\/td>\n157.48<\/td>\n30.54<\/td>\n<\/tr>\n
HDL(mg\/dL)<\/td>\nControl<\/td>\n43.73<\/td>\n5.4718<\/td>\n<0.005<\/td>\n<\/tr>\n
T2Dwithout DN<\/td>\n41.53<\/td>\n6.89<\/td>\n<\/tr>\n
DN<\/td>\n32.21<\/td>\n6.96<\/td>\n<\/tr>\n
LDL(mg\/dL)<\/td>\nControl<\/td>\n76.76<\/td>\n22.16<\/td>\n<0.036<\/td>\n<\/tr>\n
T2Dwithout DN<\/td>\n79.68<\/td>\n24.36<\/td>\n<\/tr>\n
DN<\/td>\n192.55<\/td>\n25.702<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Table 3: Univariate correlation analysis between serum levels of MMP-1, TIMP-1 and hemoglobin A1c and fasting blood glucose (FBG) in DN.<\/strong><\/p>\n\n\n\n\n\n\n
b<\/td>\nMMP-1<\/td>\nTIMP-1<\/td>\n<\/tr>\n
TIMP-1<\/td>\n0.490**<\/sup><\/td>\n–<\/td>\n<\/tr>\n
FBG<\/td>\n0.459**<\/sup><\/td>\n0.441*<\/sup><\/td>\n<\/tr>\n
HbA1c<\/td>\n0.557**<\/sup><\/td>\n0.520**<\/sup><\/td>\n<\/tr>\n<\/thead>\n<\/table>\n

**\u00a0 Correlation is significant at the 0.01 level (2-tailed).<\/p>\n

Table 4: Multiple linear regression analysis forTIMP-1 and MMP-1 in Diabetic nephropathy patients.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n\u03b2 coefficient<\/strong><\/td>\nt<\/strong><\/td>\np<\/strong><\/td>\n<\/tr>\n
TIMP-1<\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
HbA1c<\/td>\n0.55<\/td>\n4.12<\/td>\n<0.001<\/td>\n<\/tr>\n
LDL<\/td>\n0.25<\/td>\n6.095<\/td>\n<0.005<\/td>\n<\/tr>\n
HDL<\/td>\n-0.030<\/td>\n2.86<\/td>\n<0.014<\/td>\n<\/tr>\n
TG<\/td>\n0.01<\/td>\n2.515<\/td>\n<0.001<\/td>\n<\/tr>\n
MMP-1<\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
HbA1c<\/td>\n0.62<\/td>\n3.14<\/td>\n<0.001<\/td>\n<\/tr>\n
LDL<\/td>\n0.357<\/td>\n5.07<\/td>\n<0.004<\/td>\n<\/tr>\n
TG<\/td>\n0.021<\/td>\n2.66<\/td>\n<0.013<\/td>\n<\/tr>\n
HDL<\/td>\n-0.020<\/td>\n2.51<\/td>\n<0.012<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Discussion<\/strong><\/p>\n

In this study, we examined TIMP-1 and MMP-1 levels` in T2Dwith and without DN and their comparison with a control group. Also we inspected their relations with clinical features. The most applicable finding from our study is that diabetic nephropathy is related to a profound increase in serum concentrations of TIMP-1 and MMP-1.MMPs might play a role as \u201cpredictive\u201d biomarkers, as their valuation could identify a population of patients at risk.<\/p>\n

Serum TIMP-1 and MMP-9 concentrations in patients with type 2 DM have been described to be more than the control group in numerous studies9<\/sup>,<\/sup>10<\/sup>. Li and partners notified an augmented MMP-9 production during the motivation of diverse cytokines in the kidneys of diabetic rats in their study11<\/sup>. augmented concentrations of MMP-9 have been stated to participate in DN development via changing the ECM composition as well as the function and structure of podocytes,.<\/p>\n

Opposing to the above explanations, various researchers revealed that MMP-9 levels were higher in the controls than in type 2 diabetic patients. Variances in the MMPs concentrations in the serum or tissue of diabetic individuals when compared to healthy ones. As revealed by the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS), hyperglycemia is a significant factor in the diabetic complications development 12<\/sup>. Alterations in the MMPs concentrations in the serum or tissue of diabetic patients when compared with healthy controls have been authenticated in numerous researches, leading scientists to hypothesize that the levels are in agreement with the stages of diabetes and the severity of complications13<\/sup>.<\/p>\n

Our results of the positive relation between T2D and TIMP1harmonize with results from numerous case-control and cross-sectional Korean studies (cases n=80, controls n=80),14<\/sup> Iraq (cases n=54, controls n=26)15<\/sup>, the UK (cases n=86,10<\/sup> controls n=63) and the USA (n=1069).16<\/sup>Whilein Greece, a case-control study (cases n=60, controls n=60) has detected diminished concentrations of TIMP1 in T2D patients in comparison to controls, the diversified outcomes might be clarified by the altered features of patients involved in the study17<\/sup>. The varied results might be elucidated by the dissimilar features of patients comprised in the study. In comparison to all other researches, the Greek study patients were at more progressive phase of T2D and might have received additional intensified treatment. The concentrated diabetes remedy have revealed to diminish levels of TIMP1 significantly, that might elucidate for the lower levels of TIMP1 among diabetic patients in the Greek research. The alternation of MMP activity in diabetic nephropathy is likely modified by genetic factors, as an association among diabetic nephropathy and the dinucleotide polymorphism of the MMP-9 gene has been identified18<\/sup>. DN, as one of the mainly widespread complications in type 2 DM, encompasses the progressive gathering of ECM in a number of constituents of the kidney19<\/sup>. Matrix metalloproteinases are the proteolytic enzymes that are responsible for protein turnover \/degradation in the ECM, therefore abnormalities in MMP activity or expression are significant components in the progression and development of DN20<\/sup>. Genetic divergence mediating expression of MMP-2 might result in individual alterations in susceptibility to certain diseases. Recent study investigated the probable link of definite MMP-2 gene variants with the susceptibility of type 2 diabetes (T2D) in a Tunisian population, demonstrated a consistent relationship of the rs243866 and rs243865 genotype with\u00a0 a protection for T2D21<\/sup>. Moreover, previous study identified essential genes and pathways in DN using bioinformatics analysis, exploring the DN intrinsic mechanisms and discriminate new possible therapeutic and diagnostic markers of DN indicating that BTK, FOS, IRF4, JUN, PRKCB,MDFI,LCK,EGR1, NR4A1 and ALB might be the prospective novel biomarkers for diagnosis and the promising therapeutic target of DN 22<\/sup>.<\/p>\n

Conclusion<\/strong><\/p>\n

Data from the present study suggest that both MMP-1 and TIMP-1 biomarkers are risk factors for DN among Egyptian patients.<\/p>\n

Acknowledgment<\/strong><\/p>\n

The authors are thankful to the participants, National institute of diabetes and endocrinology\u00a0 and National Research Centre for the unlimited support to carry out this work.<\/p>\n

Conflict of Interest<\/strong><\/p>\n

There is no conflict of interest.<\/p>\n

Funding Sources<\/strong><\/p>\n

There is no funding source.<\/p>\n

References<\/strong><\/p>\n

    \n
  1. Birkedal-Hansen H, Moore WGI, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med<\/em>. 1993;4(2):197-250.
    \nCrossRef<\/a><\/li>\n
  2. Reynolds JJ. Collagenases and tissue inhibitors of metalloproteinases: a functional balance in tissue degradation. Oral Dis<\/em>. 1996;2(1):70-76.
    \n    CrossRef<\/a><\/li>\n
  3. Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. Jama<\/em>. 2016;316(6):602-610.
    \n    CrossRef<\/a><\/li>\n
  4. Hovind P, Tarnow L, Rossing P, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. Bmj<\/em>. 2004;328(7448):1105.
    \n    CrossRef<\/a><\/li>\n
  5. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem<\/em>. 1982;28(10):2077-2080.
    \n    CrossRef<\/a><\/li>\n
  6. Sugiuchi H, Uji Y, Okabe H, et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem<\/em>. 1995;41(5):717-723.
    \n    CrossRef<\/a><\/li>\n
  7. Wilson PW, Abbott RD, Garrison RJ, Castelli WP. Estimation of very-low-density lipoprotein cholesterol from data on triglyceride concentration in plasma. Clin Chem<\/em>. 1981;27(12):2008-2010.
    \n    CrossRef<\/a><\/li>\n
  8. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med<\/em>. 1984;310(6):341-346.
    \n    CrossRef<\/a><\/li>\n
  9. Derosa G, D\u2019angelo A, Tinelli C, et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab<\/em>. 2007;33(2):129-134.
    \n    CrossRef<\/a><\/li>\n
  10. Tayebjee MH, Nadar S, Blann AD, Beevers DG, MacFadyen RJ, Lip GYH. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens<\/em>. 2004;17(9):764-769.
    \n    CrossRef<\/a><\/li>\n
  11. Li S-Y, Huang P-H, Yang A-H, et al. Matrix metalloproteinase-9 deficiency attenuates diabetic nephropathy by modulation of podocyte functions and dedifferentiation. Kidney Int<\/em>. 2014;86(2):358-369.
    \n    CrossRef<\/a><\/li>\n
  12. Control TD, Group CDR. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int<\/em>. 1995;47(6):1703-1720.
    \n    CrossRef<\/a><\/li>\n
  13. Portik-Dobos V, Anstadt MP, Hutchinson J, Bannan M, Ergul A. Evidence for a matrix metalloproteinase induction\/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes<\/em>. 2002;51(10):3063-3068.
    \n    CrossRef<\/a><\/li>\n
  14. Lee SW, Song KE, Shin DS, et al. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. Diabetes Res Clin Pract<\/em>. 2005;69(2):175-179.
    \n    CrossRef<\/a><\/li>\n
  15. Wadood SA, Shawk RA, Hashem R. Variants of MMP-9 and TIMP-1 levels could be a predictor of an early development of cardiovascular diseases in type 2 diabetes among Iraqi patients. Iraqi J Sci<\/em>. 2015;56:622-632.<\/li>\n
  16. Hansson J, Lind L, Hulthe J, Sundstrom J. Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study. Eur J Prev Cardiol<\/em>. 2009;16(3):297-303.
    \n    CrossRef<\/a><\/li>\n
  17. Papazafiropoulou A, Perrea D, Moyssakis I, Kokkinos A, Katsilambros N, Tentolouris N. Plasma levels of MMP-2, MMP-9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus. J Diabetes Complications<\/em>. 2010;24(1):20-27.
    \n    CrossRef<\/a><\/li>\n
  18. Maeda S, Haneda M, Guo B, et al. Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. Kidney Int<\/em>. 2001;60(4):1428-1434.
    \n    CrossRef<\/a><\/li>\n
  19. Cao Z, Cooper ME. Pathogenesis of diabetic nephropathy. J Diabetes Investig 2: 243\u2013247. Link https\/\/bit ly\/2ZDkaTS<\/em>. 2011.
    \n    CrossRef<\/a><\/li>\n
  20. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Physiol<\/em>. 2007;292(3):F905-F911.
    \n    CrossRef<\/a><\/li>\n
  21. SamehSarray, Dallel M, Lamine L Ben, et al. Association of matrix metalloproteinase-2 gene polymorphisms with susceptibility to type 2 diabetes: A case control study. J Diabetes Complications<\/em>. 2021:107908. doi:https:\/\/doi.org\/10.1016\/j.jdiacomp.2021.107908
    \n    CrossRef<\/a><\/li>\n
  22. Joshi H, Vastrad B, Joshi N, Tengli A, Vastrad C, Kotturshetti I. Integrated bioinformatics analysis reveals novel key biomarkers and potential candidate small molecule drugs in diabetic nephropathy. 2020.
    \n    CrossRef<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction\u00a0 Matrix metalloproteinases (MMPs) are a family of zinc and […]<\/p>\n","protected":false},"author":15,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[99],"tags":[],"class_list":["post-44404","post","type-post","status-publish","format-standard","hentry","category-vol15no2"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/44404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=44404"}],"version-history":[{"count":5,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/44404\/revisions"}],"predecessor-version":[{"id":45060,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/44404\/revisions\/45060"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=44404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=44404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=44404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}